Literature DB >> 21343467

Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria.

Catherine Clark1, Pamela McGhee, Peter C Appelbaum, Klaudia Kosowska-Shick.   

Abstract

Ceftaroline, the active component of the prodrug ceftaroline fosamil, is a novel broad-spectrum cephalosporin with bactericidal activity against Gram-positive and -negative isolates. This study evaluated the potential for ceftaroline and comparator antibiotics to select for clones of Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, Moraxella catarrhalis, Klebsiella pneumoniae, Staphylococcus aureus, and Enterococcus faecalis with elevated MICs. S. pneumoniae and S. pyogenes isolates in the present study were highly susceptible to ceftaroline (MIC range, 0.004 to 0.25 μg/ml). No streptococcal strains yielded ceftaroline clones with increased MICs (defined as an increase in MIC of >4-fold) after 50 daily passages. Ceftaroline MICs for H. influenzae and M. catarrhalis were 0.06 to 2 μg/ml for four strains and 8 μg/ml for a β-lactamase-positive, efflux-positive H. influenzae with a mutation in L22. One H. influenzae clone with an increased ceftaroline MIC (quinolone-resistant, β-lactamase-positive) was recovered after 20 days. The ceftaroline MIC for this isolate increased 16-fold, from 0.06 to 1 μg/ml. MICs for S. aureus ranged from 0.25 to 1 μg/ml. No S. aureus isolates tested with ceftaroline had clones with increased MIC (>4-fold) after 50 passages. Two E. faecalis isolates tested had ceftaroline MICs increased from 1 to 8 μg/ml after 38 days and from 4 to 32 μg/ml after 41 days, respectively. The parental ceftaroline MIC for the one K. pneumoniae extended-spectrum β-lactamase-negative isolate tested was 0.5 μg/ml and did not change after 50 daily passages.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21343467      PMCID: PMC3088212          DOI: 10.1128/AAC.01602-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  63 in total

1.  Alterations in GyrA and ParC associated with fluoroquinolone resistance in Enterococcus faecium.

Authors:  N A el Amin; S Jalal; B Wretlind
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

2.  Canadian beta-lactamase-negative Haemophilus influenzae isolates showing decreased susceptibility toward ampicillin have significant penicillin binding protein 3 mutations.

Authors:  Michelle L Shuel; Raymond S W Tsang
Journal:  Diagn Microbiol Infect Dis       Date:  2009-02-26       Impact factor: 2.803

3.  Comparative antipneumococcal activities of sulopenem and other drugs.

Authors:  Klaudia Kosowska-Shick; Lois M Ednie; Pamela McGhee; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2009-03-23       Impact factor: 5.191

Review 4.  The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection.

Authors:  T M File; J S Tan; J F Plouffe
Journal:  Infect Dis Clin North Am       Date:  1998-09       Impact factor: 5.982

5.  Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis.

Authors:  T A Davies; L M Kelly; D B Hoellman; L M Ednie; C L Clark; S Bajaksouzian; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

6.  The other siblings: respiratory infections caused by Moraxella catarrhalis and Haemophilus influenzae.

Authors:  Larry Lutwick; Laila Fernandes
Journal:  Curr Infect Dis Rep       Date:  2006-05       Impact factor: 3.725

7.  Apparent plateau in beta-lactamase production among clinical isolates of Haemophilus influenzae and Moraxella catarrhalis in the United States: results from the LIBRA Surveillance initiative.

Authors:  Mark E Jones; James A Karlowsky; Renée Blosser-Middleton; Ian A Critchley; Clyde Thornsberry; Daniel F Sahm
Journal:  Int J Antimicrob Agents       Date:  2002-02       Impact factor: 5.283

Review 8.  Macrolide resistance in Streptococci and Haemophilus influenzae.

Authors:  Bülent Bozdogan; Peter C Appelbaum
Journal:  Clin Lab Med       Date:  2004-06       Impact factor: 1.935

Review 9.  Vancomycin resistance in Staphylococcus aureus.

Authors:  Peter C Appelbaum; Bülent Bozdogan
Journal:  Clin Lab Med       Date:  2004-06       Impact factor: 1.935

10.  Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin.

Authors:  Jeffrey B Locke; Mark Hilgers; Karen Joy Shaw
Journal:  Antimicrob Agents Chemother       Date:  2009-10-05       Impact factor: 5.191

View more
  14 in total

Review 1.  Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.

Authors:  Thomas P Lodise; Donald E Low
Journal:  Drugs       Date:  2012-07-30       Impact factor: 9.546

Review 2.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

Review 3.  Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.

Authors:  James E Frampton
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

4.  Missense mutations in PBP2A Affecting ceftaroline susceptibility detected in epidemic hospital-acquired methicillin-resistant Staphylococcus aureus clonotypes ST228 and ST247 in Western Switzerland archived since 1998.

Authors:  William L Kelley; Ambre Jousselin; Christine Barras; Emmanuelle Lelong; Adriana Renzoni
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

Review 5.  Ceftaroline Fosamil: A Review in Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2016-11       Impact factor: 9.546

6.  No decrease in susceptibility to NVC-422 in multiple-passage studies with methicillin-resistant Staphylococcus aureus, S. aureus, Pseudomonas aeruginosa, and Escherichia coli.

Authors:  Louisa D'Lima; Lisa Friedman; Lu Wang; Ping Xu; Mark Anderson; Dmitri Debabov
Journal:  Antimicrob Agents Chemother       Date:  2012-02-21       Impact factor: 5.191

Review 7.  [Resistance to "last resort" antibiotics in Gram-positive cocci: The post-vancomycin era].

Authors:  Sandra Rincón; Diana Panesso; Lorena Díaz; Lina P Carvajal; Jinnethe Reyes; José M Munita; César A Arias
Journal:  Biomedica       Date:  2014-04       Impact factor: 0.935

8.  Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections.

Authors:  Julian J Goodman; Stanley I Martin
Journal:  Ther Clin Risk Manag       Date:  2012-03-26       Impact factor: 2.423

9.  Study of Antibiotic Resistance Pattern in Methicillin Resistant Staphylococcus Aureus with Special Reference to Newer Antibiotic.

Authors:  Dardi Charan Kaur; Sadhana Sanjay Chate
Journal:  J Glob Infect Dis       Date:  2015 Apr-Jun

Review 10.  Intrinsic and acquired resistance mechanisms in enterococcus.

Authors:  Brian L Hollenbeck; Louis B Rice
Journal:  Virulence       Date:  2012-08-15       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.